open access

Vol 12, No 6 (2007)
Untitled
Published online: 2007-11-01
Submitted: 2007-06-21
Get Citation

Cisplatin-based chemotherapy: the only alternative in chemoradiation of head and neck cancer? Experience of the Institute of Oncology, Ljubljana, Slovenia

Primož Strojan
DOI: 10.1016/S1507-1367(10)60073-9
·
Rep Pract Oncol Radiother 2007;12(6):329-337.

open access

Vol 12, No 6 (2007)
Untitled
Published online: 2007-11-01
Submitted: 2007-06-21

Abstract

Background

Concomitant chemoradiation is a widely used therapeutic concept in intensified locoregional treatment of high risk head and neck cancer patients. In this context, cisplatin monotherapy or in combination with other chemotherapeutics is recognized as the most effective drug to be added to radiotherapy.

Aim

The aim of this review is to present the rationale for combining radiotherapy with cisplatin in the treatment of head and neck cancer and to summarize the experience of the Institute of Oncology Ljubljana, Slovenia, gained through two prospective randomized trials on chemoradiation with mitomycin C and bleomycin in operable as well as inoperable head and neck cancer patients. Furthermore, recent developments in technology and biological drug modeling are discussed, which are considered to have a potential to add significantly to the locoregional effectiveness of radiotherapy.

Materials/Methods

References were retrieved using the online data base of the National Library of Medicine (PubMed: [[ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/PubMed"]]http://www.ncbi.nlm.nih.gov/PubMed). Terms used included: head and neck carcinoma, squamous cell carcinoma, concomitant chemoradiotherapy, cisplatin, mitomycin C, bleomycin. The results of studies using cisplatin-based chemoradiation regimens in the treatment of patients with inoperable tumors and on postoperative stetting were compared with the results of the studies, conducted at the Institute of Oncology and ENT Department at the Clinical Center Ljubljana, Slovenia.

Results

When comparing mitomycin C-bleomycin chemotherapy with other comparable series on exclusively inoperable oropharyngeal cancer, but with cisplatin (or carboplatin) and 5-fluorouracil chemotherapy, and to standard dose cisplatin regimen used in postoperative setting, the effectiveness of our unconventional drug combination appeared to be at least equivalent to the well established platinum-based chemotherapy standard.

Conclusions

At the moment, concomitant chemoradiation with cisplatin-based chemotherapy is the most widely used way for potentiation of locoregional effect of radiotherapy in high risk head and neck cancer patients. Our clinical experiences with mitomycin C and bleomycin chemoradiation showed that there was still a window of opportunity to achieve equivalent clinical results with other drug combinations.

Abstract

Background

Concomitant chemoradiation is a widely used therapeutic concept in intensified locoregional treatment of high risk head and neck cancer patients. In this context, cisplatin monotherapy or in combination with other chemotherapeutics is recognized as the most effective drug to be added to radiotherapy.

Aim

The aim of this review is to present the rationale for combining radiotherapy with cisplatin in the treatment of head and neck cancer and to summarize the experience of the Institute of Oncology Ljubljana, Slovenia, gained through two prospective randomized trials on chemoradiation with mitomycin C and bleomycin in operable as well as inoperable head and neck cancer patients. Furthermore, recent developments in technology and biological drug modeling are discussed, which are considered to have a potential to add significantly to the locoregional effectiveness of radiotherapy.

Materials/Methods

References were retrieved using the online data base of the National Library of Medicine (PubMed: [[ce:inter-ref xlink:href="http://www.ncbi.nlm.nih.gov/PubMed"]]http://www.ncbi.nlm.nih.gov/PubMed). Terms used included: head and neck carcinoma, squamous cell carcinoma, concomitant chemoradiotherapy, cisplatin, mitomycin C, bleomycin. The results of studies using cisplatin-based chemoradiation regimens in the treatment of patients with inoperable tumors and on postoperative stetting were compared with the results of the studies, conducted at the Institute of Oncology and ENT Department at the Clinical Center Ljubljana, Slovenia.

Results

When comparing mitomycin C-bleomycin chemotherapy with other comparable series on exclusively inoperable oropharyngeal cancer, but with cisplatin (or carboplatin) and 5-fluorouracil chemotherapy, and to standard dose cisplatin regimen used in postoperative setting, the effectiveness of our unconventional drug combination appeared to be at least equivalent to the well established platinum-based chemotherapy standard.

Conclusions

At the moment, concomitant chemoradiation with cisplatin-based chemotherapy is the most widely used way for potentiation of locoregional effect of radiotherapy in high risk head and neck cancer patients. Our clinical experiences with mitomycin C and bleomycin chemoradiation showed that there was still a window of opportunity to achieve equivalent clinical results with other drug combinations.

Get Citation

Keywords

head and neck carcinoma; squamous cell carcinoma; concomitant chemoradiotherapy; cisplatin; mitomycin C; bleomycin

About this article
Title

Cisplatin-based chemotherapy: the only alternative in chemoradiation of head and neck cancer? Experience of the Institute of Oncology, Ljubljana, Slovenia

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 12, No 6 (2007)

Pages

329-337

Published online

2007-11-01

DOI

10.1016/S1507-1367(10)60073-9

Bibliographic record

Rep Pract Oncol Radiother 2007;12(6):329-337.

Keywords

head and neck carcinoma
squamous cell carcinoma
concomitant chemoradiotherapy
cisplatin
mitomycin C
bleomycin

Authors

Primož Strojan

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl